Verastem Poised for Breakout with Imminent FDA Approval
AI Prediction of Verastem, Inc. (VSTM)
Verastem, a biopharmaceutical company, is on the cusp of potentially transformative growth with its focus on RAS/MAPK pathway-driven cancers. The upcoming catalysts, including the possible FDA approval of its leading drug candidates avutometinib and defactinib for low-grade serous ovarian cancer, could significantly impact its market valuation and operational dynamics. Considering the strategic alignment with industry requirements and the anticipation surrounding its clinical results, Verastem presents a compelling investment opportunity with considerable upside potential.
VSTM Report Information
Prediction Date2025-07-03
Close @ Prediction$4.80
Mkt Cap624m
IPO DateN/a
AI-derived Information
Recent News for VSTM
- Aug 7, 1:10 am — Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ... (GuruFocus.com)
- Aug 6, 4:19 pm — Verastem: Q2 Earnings Snapshot (Associated Press)
- Aug 6, 4:01 pm — Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
- Jul 28, 4:01 pm — Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer (Business Wire)
- Jul 23, 7:30 am — Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
- Jul 22, 4:01 pm — Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer (Business Wire)
- Jul 2, 4:30 pm — Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- Jun 23, 4:01 pm — VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors (Business Wire)
- Jun 17, 8:52 am — VSTM files 8-K with clinical-trial language (ScanScor Filing Bot)
- Jun 17, 7:30 am — Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer (Business Wire)
- Jun 16, 4:01 pm — Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer (Business Wire)
- Jun 15, 4:01 pm — Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program (Business Wire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.